Little Green Pharma (ASX: LGP) to acquire Cannatrek in all-share deal creating vertically integrated cannabis leader

Little Green Pharma Limited, listed on the Australian Securities Exchange under the ticker ASX: LGP, has announced the acquisition of 100 percent of Cannatrek Limited through a scheme of arrangement. The transaction, confirmed on 14 January 2026, marks one of the most significant mergers in Australia’s medicinal cannabis sector. The combined entity, referred to by both parties as the “Combined Group,” will be a vertically integrated company spanning cultivation, GMP-certified manufacturing, packaging, digital health platforms, and international distribution networks across Australia and Europe.

The pro forma financials of the new group are already attracting investor attention. Based on the 2025 financial year, the combined company would have generated approximately 112 million Australian dollars in revenue and 13 million Australian dollars in adjusted EBITDA, with consolidated cash of nearly 15 million Australian dollars and over 136 million Australian dollars in net assets. This level of revenue scale and positive cash generation is rare in an industry still characterized by fragmented players, regulatory variability, and capital-intensive operations. The merger, if implemented as outlined, may signal a shift toward maturity and strategic consolidation in the sector.

What strategic priorities are driving the merger and how are the ownership mechanics structured?

Under the agreed scheme of arrangement, existing shareholders of Cannatrek will receive 1.835806 new ordinary shares in Little Green Pharma for each Cannatrek share, along with 0.727502 contingent value shares. These contingent value shares are designed to account for post-transaction liabilities and other unknowns and may later convert to ordinary shares depending on the balance of liabilities between the two merging entities.

At the outset, Cannatrek shareholders will hold 60.5 percent of the fully diluted issued capital in Little Green Pharma, with the potential to increase their stake to 68.2 percent depending on net outcomes from potential liabilities. Existing shareholders of Little Green Pharma will hold approximately 39.5 percent of the merged group on a fully diluted basis at completion. The contingent value mechanism creates a sliding scale that adjusts final ownership based on a range of potential outcomes, ensuring that both parties have skin in the game regarding operational and financial exposures in the post-merger environment.

Importantly, the contingent value shares carry no voting rights, are non-transferable, and do not pay dividends. They are designed solely to rebalance equity depending on financial outcomes that emerge within a two-year window following completion. Conversion will only occur once those conditions are resolved, and only then will they convert to ordinary shares tradable on the Australian Securities Exchange.

How does this merger reposition the combined group for European expansion and global competitiveness?

While Australia remains a strong base for both companies, it is increasingly clear that Europe represents the major future revenue engine. The merger gives Little Green Pharma access to Cannatrek’s stronger balance sheet and cash position, which will help unlock underutilised assets in Denmark. The Denmark facility, already the largest EU-GMP certified medicinal cannabis production site in Europe, has been operating below capacity. With Cannatrek’s capital, Little Green Pharma now has the opportunity to invest in yield optimization, packaging automation, and differentiated product formulations for export markets.

Cannatrek brings not just capital but also high-volume, high-frequency domestic distribution capabilities. It owns and operates a GMP-certified facility in Australia and runs the widely used digital platforms Greenship and MyEden. Greenship serves as a business-to-business platform connecting pharmacies to a curated range of medicinal cannabis products, while MyEden offers telehealth services, prescription management, and direct-to-patient fulfillment. These platforms can now be expanded to integrate with Little Green Pharma’s product lines and European operations, creating a digital distribution bridge between continents.

By combining production and packaging scale in Europe with domestic distribution infrastructure in Australia, the merged company is better positioned to serve both cost-sensitive markets and premium jurisdictions that demand EU-GMP compliance, such as Germany, France, and the United Kingdom.

What are the operational synergies and execution risks?

Cannatrek and Little Green Pharma have identified multiple synergy vectors. These include rationalising overlapping clinic and distribution infrastructure, leveraging Cannatrek’s GMP-certified Australian manufacturing capacity, and aligning Cannatrek’s top-selling product portfolio with Little Green Pharma’s cultivation footprint in both Australia and Denmark.

The companies are also combining eight medicinal cannabis brands into one unified product and pricing architecture. This is expected to broaden market coverage across patient needs and support improved price point optimization. Cannatrek currently owns what is believed to be the top-selling medicinal cannabis flower product in Australia, giving the Combined Group a strong retail benchmark to defend and build upon.

Integration will not be without risk. Operational integration across geographies, harmonisation of digital systems, and the transfer of brand portfolios into regulated European markets all require technical precision and regulatory navigation. However, both companies have track records in executing M&A. Cannatrek successfully acquired and integrated Heyday, while Little Green Pharma integrated HHI into its operations in a prior acquisition. This merger builds on demonstrated playbooks rather than hypothetical synergies.

How is governance, leadership, and escrow structured to support post-merger stability?

Leadership continuity has been designed into the merger structure. Brent Dennison, currently Chair of Cannatrek, will become Chair of the Combined Group. Paul Long, Managing Director of Little Green Pharma, will serve as Group Chief Executive Officer. Jason Rance, Chief Executive Officer of Cannatrek, will lead the Australian operations, while Cannatrek Chief Financial Officer Paula Bulter becomes Group Chief Financial Officer.

A five-member board will be finalised before the Scheme booklet is distributed, with three directors coming from Cannatrek and two from Little Green Pharma. The new entity will operate under existing structures until implementation, at which point the new governance model will take effect.

In addition, key shareholders on both sides have entered voluntary escrow arrangements. Major Cannatrek shareholders representing more than 1.5 percent of equity will be locked into six- and twelve-month escrow agreements. On the Little Green Pharma side, major shareholders including Tiga Trading and entities associated with Thorney Investments and the Managing Director will mirror those lock-up provisions. These collectively amount to 46 percent of the merged entity’s shares being locked for six to twelve months, providing stability in the early post-merger trading period.

What is the shareholder approval process and deal timeline?

Both companies have laid out a clear roadmap toward implementation. Cannatrek shareholders will vote on the Scheme at a meeting scheduled for 2 April 2026, with the Scheme Booklet expected to be dispatched on 4 March 2026. Little Green Pharma will hold a separate shareholder meeting on the same day to approve the issuance of new shares as part of the scheme consideration.

The deal is expected to reach court approval on 21 April 2026, with the effective date set for 22 April and implementation scheduled for 1 May 2026. These dates are subject to court availability and other regulatory timelines but provide investors with a structured path to completion.

Cannatrek has appointed RSM Corporate Australia as the Independent Expert to assess the fairness of the deal, with the report to be included in the Scheme Booklet. Legal and financial advisers for Little Green Pharma include Hamilton Locke and Canaccord Genuity, respectively. Cannatrek’s legal and financial advisers are K&L Gates and Intrinsic Partners.

What broader signals does this merger send to the global cannabis market?

This merger is a strong signal that Australia’s cannabis industry is entering a consolidation phase. The high fixed costs of GMP certification, the need for international distribution reach, and the shift toward digital patient engagement are forcing mid-sized players to merge or risk marginalisation.

Little Green Pharma and Cannatrek are not just merging assets—they are fusing infrastructure, digital platforms, and regulatory pathways to build a scalable export business. In a global industry still dominated by fragmented operators and speculative business models, this is a rare example of disciplined capital allocation, operational integration planning, and international market alignment.

Investors will be watching closely to see whether this merger can catalyse similar deals across other ASX-listed cannabis players or draw attention from international players looking to enter the European market via Australian platforms.

Key takeaways on what this merger means for the companies, investors, and the cannabis sector

• Little Green Pharma will acquire 100 percent of Cannatrek in an all-scrip transaction that forms one of the largest vertically integrated medicinal cannabis groups in Australia and Europe.

• Cannatrek shareholders will hold 60.5 percent of the Combined Group on a fully diluted basis, with potential upside to 68.2 percent via contingent value shares that depend on post-merger liability outcomes.

• The Combined Group would have posted pro forma FY2025 revenues of approximately 112 million Australian dollars, with adjusted EBITDA of 13 million Australian dollars and nearly 15 million Australian dollars in cash.

• Operational synergies include manufacturing integration, cross-border clinic and distribution alignment, and enhanced product portfolio coordination across eight brands.

• The Denmark facility operated by Little Green Pharma is expected to become a growth engine for European expansion, backed by Cannatrek’s capital and product pipeline.

• Digital platforms such as Greenship and MyEden will provide integrated B2B and B2C capabilities, connecting cultivation to patients across multiple jurisdictions.

• Escrow agreements cover nearly half of all shares in the merged entity, adding post-deal trading stability and protecting long-term strategic execution.

• Shareholder votes for both companies are scheduled for April 2026, with implementation targeted for 1 May 2026, pending all regulatory and judicial approvals.